Brief: Scilex Holding Company Announces Complete Enrollment Of A Phase 2 Study To Evaluate The Safety And Efficacy Of Sp-103 (Lidocaine Topical System)
04/05/2023 14:12
May 4 (Reuters) - Scilex Holding Co SCLX.O :
* SCILEX HOLDING COMPANY ANNOUNCES COMPLETE ENROLLMENT OF A
PHASE
2 STUDY TO EVALUATE THE SAFETY AND EFFICACY OF SP-103 (LIDOCAINE
TOPICAL SYSTEM) 5.4%, TRIPLE STRENGTH FORMULATION OF ZTLIDO®,
FOR THE TREATMENT OF ACUTE LOW BACK PAIN
* SCILEX HOLDING CO - TOP-LINE DATA FROM PHASE 2 STUDY IS
EXPECTED
IN Q3-2023
Source text for Eikon: ID:nGNX8BMTnq
Further company coverage: SCLX.O
Recent news on Scilex Holding
See all newsEnters Promissory Note With Vivasor For Revolving Credit Up To $20 Million, On Aug 8
Brief: Scilex Holding Company Announces Dream Bowl I Meme Coin Tokens To List On Biconomy Exchange As Early As June 23, 2026
Brief: O+C Private Credit Wade Defendants Dispute Complaint And Statement By Scilex Holding Company
Company Enters Binding Term Sheet With Datavault Ai - SEC Filing
Company May Offer Up To $500 Million In Securities - SEC Filing